
Adamis Pharmaceuticals Corporation ADMP
Quarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Operating Expenses 2011-2026 | ADMP
Annual Operating Expenses Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 38.9 M | 35.7 M | 44.7 M | 30.3 M | 26.8 M | 13.9 M | 4.4 M | 3.22 M | 4.82 M | 6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.7 M | 3.22 M | 20.9 M |
Operating Expenses of other stocks in the Drug manufacturers industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
40.3 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
30.5 M | - | 10.11 % | $ 58.2 M | ||
|
Aerie Pharmaceuticals
AERI
|
213 M | - | - | $ 754 M | ||
|
Catalent
CTLT
|
512 M | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
113 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
763 M | - | - | $ 28.9 M | ||
|
DURECT Corporation
DRRX
|
44.6 M | - | - | $ 50.1 M | ||
|
Alimera Sciences
ALIM
|
71.8 M | - | - | $ 142 M | ||
|
Athenex
ATNX
|
96.7 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
196 M | - | - | $ 2.06 B | ||
|
Evoke Pharma
EVOK
|
12.6 M | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
35.2 M | $ 3.05 | -2.24 % | $ 42.9 M | ||
|
Cronos Group
CRON
|
154 M | $ 2.58 | 0.19 % | $ 1.33 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
213 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
106 M | - | 2.45 % | $ 38.1 M | ||
|
Sundial Growers
SNDL
|
102 K | $ 1.41 | 2.55 % | $ 3.37 M | ||
|
Bausch Health Companies
BHC
|
4.96 B | $ 5.71 | -0.26 % | $ 2.08 B | ||
|
Tilray
TLRY
|
1.52 B | $ 6.89 | 2.53 % | $ 4.26 B | ||
|
Harrow Health
HROW
|
174 M | $ 37.97 | 2.35 % | $ 1.4 B | ||
|
Aurora Cannabis
ACB
|
183 M | $ 3.53 | 1.44 % | $ 86.3 M | ||
|
Canopy Growth Corporation
CGC
|
197 M | $ 1.09 | 0.46 % | $ 117 M | ||
|
Veru
VERU
|
44 M | $ 2.39 | 0.42 % | $ 322 M | ||
|
Jupiter Wellness
JUPW
|
12.5 M | - | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
41.4 M | $ 1.43 | 1.04 % | $ 402 M | ||
|
Lannett Company
LCI
|
209 M | - | 1.15 % | $ 7.11 M | ||
|
Viatris
VTRS
|
5.67 B | $ 13.97 | 0.98 % | $ 16.8 B | ||
|
Neoleukin Therapeutics
NLTX
|
103 M | - | - | $ 193 M | ||
|
Evolus
EOLS
|
107 M | $ 4.39 | 1.5 % | $ 283 M | ||
|
Emergent BioSolutions
EBS
|
558 M | $ 8.53 | 3.52 % | $ 437 M | ||
|
Organogenesis Holdings
ORGO
|
368 M | $ 2.47 | 3.57 % | $ 325 M | ||
|
Pacira BioSciences
PCRX
|
279 M | $ 23.72 | -1.41 % | $ 1.1 B | ||
|
PetIQ
PETQ
|
138 M | - | 1.64 % | $ 400 M | ||
|
ProPhase Labs
PRPH
|
47.1 M | - | - | $ 5.07 M | ||
|
Relmada Therapeutics
RLMD
|
59.1 M | $ 7.24 | -1.9 % | $ 286 M | ||
|
Assertio Holdings
ASRT
|
133 M | $ 18.02 | 0.03 % | $ 115 M | ||
|
Radius Health
RDUS
|
304 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
22.5 M | - | -4.76 % | $ 65.3 M | ||
|
cbdMD
YCBD
|
28.9 M | $ 0.73 | -2.42 % | $ 3.15 M | ||
|
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
36.7 M | $ 1.03 | 1.98 % | $ 51.4 M | ||
|
PLx Pharma
PLXP
|
44.2 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
179 M | $ 8.24 | -1.73 % | $ 721 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
9.18 M | $ 2.17 | -7.66 % | $ 2.69 M | ||
|
Zomedica Corp.
ZOM
|
14.1 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
35.3 M | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
31.1 M | $ 0.91 | -2.76 % | $ 32.7 M | ||
|
Tricida
TCDA
|
153 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
3.11 M | $ 0.63 | -3.05 % | $ 2.7 M | ||
|
TherapeuticsMD
TXMD
|
7.41 M | $ 2.15 | 4.63 % | $ 24.9 M |